Last updated: September 5, 2026
The ingredient combination corresponds to Lactated Ringer’s and 5% Dextrose Injection, USP, also called Dextrose 5% in Lactated Ringer’s. It is a sterile intravenous crystalloid containing dextrose, sodium chloride, sodium lactate, potassium chloride and calcium chloride. The product is a mature, largely generic hospital commodity with low patent protection, limited pricing power and financial performance driven by manufacturing capacity, hospital contracts, supply continuity and production costs rather than molecule-level exclusivity.
What is the drug formulation and how is it used?
Lactated Ringer’s and 5% Dextrose Injection is an intravenous fluid used for fluid and electrolyte replacement, perioperative care, dehydration and selected situations requiring both crystalloid volume and glucose. The lactate component is metabolized primarily to bicarbonate and contributes to an alkalinizing effect. The product is not the same as plain Lactated Ringer’s, which does not contain dextrose.
A representative formulation per 100 mL contains approximately:
| Component |
Approximate amount per 100 mL |
Clinical function |
| Dextrose |
5 g |
Carbohydrate and limited energy supply |
| Sodium chloride |
0.6 g |
Sodium and chloride replacement |
| Sodium lactate |
0.31 g |
Buffer precursor |
| Potassium chloride |
0.03 g |
Potassium replacement |
| Calcium chloride |
0.02 g |
Calcium replacement |
| Water for injection |
q.s. |
Intravenous vehicle |
The product is supplied in large-volume parenteral containers, commonly 250 mL, 500 mL and 1,000 mL bags. Exact concentrations and container sizes vary by manufacturer and market.
FDA labeling identifies important limitations. The solution is not a blood transfusion diluent because the calcium content can interfere with citrate anticoagulation. Compatibility with ceftriaxone requires particular caution, especially in neonates. Hyperglycemia, fluid overload, electrolyte imbalance and metabolic complications are potential risks depending on the patient and infusion rate (U.S. Food and Drug Administration, n.d.-a).
What is the FDA regulatory status of Dextrose 5% in Lactated Ringer’s?
The product is an FDA-approved prescription intravenous solution regulated as a drug. It is generally marketed through abbreviated new drug applications or legacy approved applications for generic parenteral products. The active ingredients are long-established and have no meaningful new chemical entity exclusivity.
Regulatory differentiation is based mainly on:
- Sterility assurance and container-closure integrity
- Manufacturing process validation
- Stability and shelf-life
- Extractables and leachables
- Particulate and endotoxin control
- Electrolyte and dextrose concentration accuracy
- Container size and administration-system compatibility
- Labeling for pediatric, neonatal and compatibility restrictions
Large-volume parenteral manufacturers must comply with current good manufacturing practice requirements and FDA controls for sterile drug production. FDA drug shortages have repeatedly shown that production interruptions, raw-material constraints and limited manufacturing redundancy can affect hospital supply even when products have no patent barriers (U.S. Food and Drug Administration, n.d.-b).
What patents protect calcium chloride, dextrose, potassium chloride, sodium chloride and sodium lactate injection?
The formulation has little practical patent protection in the United States. The individual ingredients are long-established generic substances, and the combination has been marketed for decades. Product-level patent rights, if any, are unlikely to create a meaningful barrier to an ANDA-based competitor.
| IP category |
Commercial relevance |
| Active-ingredient patents |
None expected for these established electrolytes and dextrose |
| New chemical entity exclusivity |
Not applicable |
| Formulation patents |
Limited; potential claims may concern specific concentrations, containers or stability characteristics |
| Method-of-use patents |
No broad blocking indication patent expected |
| Manufacturing patents |
Possible for bag construction, mixing, sterilization or process controls, but usually narrow |
| Device and container patents |
Possible for proprietary administration systems or multilayer bags |
| Trade secrets |
Relevant to process yield, filling, sterilization and quality control |
| Orange Book protection |
Generally limited or absent for this commodity combination |
The main IP risk is not a blocking composition-of-matter patent. It is the cost and technical difficulty of qualifying a sterile manufacturing process and maintaining reliable commercial supply. A competitor can have legal freedom to market the product while still facing substantial operational barriers.
What is the Orange Book status of Dextrose 5% in Lactated Ringer’s?
The Orange Book does not create the same exclusivity structure for this product that it creates for patented small-molecule branded medicines. Plain electrolyte and dextrose injections are typically marketed as multisource generic products. Any listed patents would need to be evaluated by specific product, strength, dosage form and application number.
The practical regulatory path is an ANDA or another applicable abbreviated pathway, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where relevant, sterility, quality and labeling. Because the product is administered intravenously and has a straightforward composition, the competitive focus is usually on chemistry, manufacturing and controls rather than clinical differentiation.
When does this product lose exclusivity?
The product has effectively already lost conventional exclusivity. It is a mature generic intravenous fluid rather than a recently launched branded medicine. There is no expected patent cliff comparable to that of a protected biologic or a novel oral small molecule.
Market entry can occur when a manufacturer obtains the required FDA approval and establishes compliant sterile production. Commercial barriers remain because:
- Large-volume sterile facilities require substantial capital.
- Production slots are constrained.
- Hospitals often use group purchasing organization contracts.
- Buyers value supply reliability and shortage performance.
- Switching suppliers requires quality qualification and operational coordination.
The result is a market with low legal exclusivity but persistent operational concentration.
How many manufacturers compete in this market?
Competition varies by country, container type and current shortage conditions. In the United States, major parenteral-fluid suppliers have included Baxter, B. Braun, ICU Medical through its Hospira operations, Fresenius Kabi and other approved generic manufacturers. Product availability can change as companies add capacity, discontinue presentations or experience production interruptions.
| Competitive factor |
Effect on the market |
| Number of approved suppliers |
More suppliers reduce long-term pricing power |
| Number of active suppliers |
A smaller active set increases shortage risk |
| Hospital contract concentration |
Favors scale manufacturers |
| Container format |
Creates switching costs |
| Production footprint |
Determines resilience during disruptions |
| Freight and storage cost |
Important because the product is heavy and low value per unit |
| Shortage history |
Can temporarily increase prices and reorder volumes |
The relevant competitive unit is often the hospital supply contract rather than the prescription. Buyers typically evaluate a basket of large-volume parenterals, including plain dextrose, saline, Lactated Ringer’s, Dextrose 5% in Lactated Ringer’s and other electrolyte solutions.
What drives the financial trajectory of this drug?
The financial trajectory is structurally low-growth but can be volatile. Unit demand is relatively defensive because hospitals use crystalloid fluids in surgery, emergency care, inpatient medicine, obstetrics and critical care. Revenue expansion generally comes from volume, price adjustments and capacity availability rather than clinical innovation.
Revenue drivers
- Hospital admissions and surgical volumes
- Emergency-department activity
- Mix of 250 mL, 500 mL and 1,000 mL bags
- Contract renewals with hospitals and group purchasing organizations
- Temporary price increases during shortages
- New production capacity
- International tender awards
- Demand for ready-to-use sterile bags
Margin pressures
- Plastic resin and container costs
- Energy and water costs
- Sterilization and quality-control expense
- Freight costs
- Labor for aseptic manufacturing
- Regulatory remediation
- Product recalls and destruction of inventory
- Contractual price compression
- Underutilized manufacturing capacity
Public companies generally do not report revenue for this precise formulation separately. It is usually included within broader hospital products, infusion therapy or generic injectables segments. A precise product-level revenue figure therefore cannot be derived reliably from public filings.
How does this product compare with plain Lactated Ringer’s and normal saline?
| Product |
Dextrose |
Buffer/lactate |
Key commercial position |
| Dextrose 5% in Lactated Ringer’s |
5% |
Yes |
Niche combination product |
| Lactated Ringer’s |
None |
Yes |
Broad crystalloid use |
| 0.9% Sodium Chloride |
None |
No |
High-volume standard fluid |
| Dextrose 5% in water |
5% |
No |
Glucose and free-water administration |
| Plasma-Lyte-type balanced fluid |
Usually none |
Acetate/gluconate, depending on product |
More differentiated balanced crystalloid |
Dextrose 5% in Lactated Ringer’s has a narrower clinical role than plain saline or Lactated Ringer’s. Its value is the combined delivery of glucose and balanced electrolytes. That combination can support demand in specific perioperative and replacement settings, but it also limits the product’s addressable volume compared with the largest crystalloid categories.
What generic entry risks exist?
Generic entry risk is high in legal terms because the formulation is mature and generally unprotected. Commercial entry risk is more complex.
A new entrant may face:
- Difficulty obtaining validated sterile production capacity
- Inability to match incumbent delivery reliability
- Hospital reluctance to qualify a low-volume supplier
- Limited profitability under group purchasing contracts
- High costs for inventory and nationwide distribution
- Exposure to FDA inspection findings
- Container or administration-set compatibility issues
For incumbent manufacturers, the principal threat is not a single Paragraph IV challenge. It is cumulative price erosion from multiple approved suppliers, hospital contract rebidding and substitution toward alternative balanced crystalloids.
What patent litigation and Paragraph IV challenges affect the product?
No major blocking patent litigation or high-profile Paragraph IV dispute is generally associated with the mature composition of Dextrose 5% in Lactated Ringer’s. Paragraph IV risk is more relevant to proprietary container systems, novel premixed formulations or branded electrolyte products with formulation-specific patents.
For this product, litigation exposure is more likely to involve:
- Manufacturing defects
- Product contamination
- Labeling and compatibility claims
- Supply contracts
- Recall-related liability
- Trade-secret disputes
- Container or delivery-system technology
The low patent burden reduces litigation cost but also reduces the ability of a supplier to defend premium pricing.
How strong is the patent estate?
The composition patent estate is weak. The commercial moat is moderate only where a manufacturer controls scarce sterile capacity, hospital contracts, a qualified container platform or a reliable distribution network.
| Asset |
Estimated strategic strength |
| Composition-of-matter IP |
Very weak |
| Method-of-use IP |
Weak |
| Formulation IP |
Weak to moderate if narrowly claimed |
| Container technology |
Moderate in a defined system |
| Manufacturing know-how |
Moderate |
| Regulatory approvals |
Moderate |
| Hospital contracts |
Moderate |
| Sterile production capacity |
Strongest practical barrier |
The product is therefore best analyzed as a manufacturing and procurement asset, not a patent-protected pharmaceutical franchise.
What is the long-term financial outlook?
The base-case outlook is stable demand with limited organic growth and periodic pricing volatility. Revenue should track hospital utilization, procedure volumes and inflation more closely than pharmaceutical innovation.
Base case
Steady hospital demand, modest price increases and gradual margin pressure from procurement contracts. This is the most likely long-term trajectory.
Upside case
A shortage affecting competing suppliers, new hospital contracts, successful capacity expansion or improved mix toward higher-value container formats can produce temporary revenue and margin growth.
Downside case
A new low-cost supplier, excess industry capacity, contract repricing, manufacturing remediation or substitution toward other balanced fluids can reduce realized pricing and profitability.
The investment profile is defensive on volume but exposed to operational execution. Companies with diversified sterile-injectable portfolios, multiple production sites and strong hospital distribution are better positioned than single-product entrants.
What are the key takeaways for investors and pharmaceutical companies?
- The ingredient combination is a mature generic IV fluid, not a patent-protected growth drug.
- FDA exclusivity and Orange Book barriers are minimal.
- Paragraph IV litigation is unlikely to be the central competitive issue.
- Sterile manufacturing, supply continuity and hospital contracts determine commercial performance.
- Product-level revenue is generally not disclosed by public companies.
- Demand is stable, but pricing is vulnerable to procurement pressure and new capacity.
- Shortages can create temporary financial upside and substantial operational risk.
- The strongest defensible assets are validated production capacity, reliable distribution and customer contracts.
FAQs about Dextrose 5% in Lactated Ringer’s
Is Dextrose 5% in Lactated Ringer’s the same as Lactated Ringer’s?
No. Dextrose 5% in Lactated Ringer’s contains 5% dextrose in addition to the electrolytes and sodium lactate found in Lactated Ringer’s.
Is this product a biologic or biosimilar?
No. It is a conventional sterile small-molecule drug product. Biosimilar regulation does not apply.
Does the product have a meaningful composition patent?
No broad, commercially significant composition patent is expected for the established combination of calcium chloride, dextrose, potassium chloride, sodium chloride and sodium lactate.
Which companies have the strongest commercial position?
Large sterile-injectable suppliers such as Baxter, B. Braun, ICU Medical through Hospira operations and Fresenius Kabi have historically had the strongest infrastructure and hospital-market access, although active supply positions vary by product and period.
Can a shortage materially improve manufacturer profitability?
Yes, temporarily. Shortages can increase realized pricing and order volumes, but they also raise regulatory, quality, logistics and customer-service risks. The effect is usually episodic rather than a durable change in product economics.
References
-
U.S. Food and Drug Administration. (n.d.-a). Lactated Ringer’s and 5% Dextrose Injection, USP: Prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Drug shortages: Current and resolved drug shortages and risk-management resources. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-d). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.-e). Current good manufacturing practice requirements for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations**
